In the span of a season, a global cadre of researchers has leveraged
years of drug development into a slew of possible treatments for severe acute
respiratory syndrome (SARS). Since the beginning of the SARS outbreak last
spring, large drug companies have dusted off libraries of failed antivirals,
famous researchers have adapted the latest anti-HIV strategy, and federal
agencies have busied themselves screening thousands of existing drugs.